Evidence / Jenks et al. · 2012
S-equol compared with soy isoflavones
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, double-blind, active-comparator human pilot.
- Product relevance
- Branded ingredient evidence for an external S-equol preparation.
- Sample or population
- 102 postmenopausal women aged 45–65 with at least five daily hot flashes.
- Studied dose
- 10, 20 or 40 mg/day of S-equol, or soy isoflavones. The abstract does not report the comparator amount.
- Duration
- 8 weeks.
- Finding
- Hot-flash frequency reductions at week 8 were similar across groups. Differences were reported for the highest dose in a cumulative analysis and for higher doses in a subgroup with more frequent baseline hot flashes.
- Limitations
- There was no inert placebo arm. Secondary and subgroup findings do not establish superiority at the final visit.
- Study quality
- Active-comparator pilot with multiple analyses. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.